In patients with severe obesity, metabolic and bariatric surgery was linked to a lower risk for inflammatory bowel disease ...
A new systematic review and meta-analysis of studies presented at this year's European Congress on Obesity in Istanbul, ...
Despite a sharp uptick in the use of GLP-1 receptor agonists, most US adults with severe obesity do not receive treatment.
Metabolic bariatric surgery use declined by 34.1% from 2022 through 2024, whereas GLP-1 prescriptions increased by more than ...
Preoperative weight loss with medications does not meaningfully diminish the effectiveness of bariatric surgery.
Significantly greater decrease seen in lifetime ASCVD risk following MBS versus GLP-1 RA therapy, plus greater percent total body weight loss.
New research presented at this year's European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that ...
Patients often feel sudden shortness of breath, sharp chest pain that worsens with breathing, a rapid heartbeat, dizziness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results